This bill creates a new statutory requirement that health carriers must cover diagnosis and treatment of the chronic disease of obesity for health plans issued or renewed on or after January 1, 2026. Required covered services are intensive health behavior and lifestyle treatment, metabolic and bariatric surgery, and U.S. FDA‑approved obesity medications. It forbids coverage criteria for FDA‑approved obesity medications that are more restrictive than the FDA‑approved indications, requires that deductibles, copayments, coinsurance and benefit‑year maximums for obesity treatments be no different from those for any other illness or condition, and allows utilization management only if medical necessity and appropriateness are determined in the same manner as for other covered conditions. The bill permits intensive health behavior and lifestyle treatment to include interventions that are CDC‑certified or recognized or those recommended by current clinical standards. The act reenacts and amends RCW 41.05.017 to make health plans under that chapter subject to a specified list of RCWs and to the new coverage requirement created in section 1 of this act. It requires the named authority to apply to the federal Centers for Medicare and Medicaid Services (CMS) by November 1, 2025 for authorization to receive matching federal funds to provide the services described, and, upon federal authorization, requires the authority and all managed care organizations to provide the same obesity treatment coverage and to follow the same limits on medication criteria and utilization management as applied to health carriers. The text adds definitions for “intensive health behavior and lifestyle treatment,” “FDA‑approved obesity medication,” and “metabolic and bariatric surgery,” and cross‑references telemedicine definitions in other RCWs. This is a mix of a new law creating mandated coverage and procedural changes to existing law (reenactment/amendment of RCW 41.05.017 and a CMS application requirement). The extracted facts do not identify which specific agency is meant by the term “authority,” do not include the telemedicine definitions cited, and do not provide the full text of the reenacted RCW 41.05.017 or any provisions, if any, related to diabetes prevention that appear in the act title.

If enacted, most commercial health insurers and public managed care plans will have to add routine coverage for diagnosis and treatment of obesity for plans issued or renewed on or after January 1, 2026, including intensive behavioral/lifestyle programs, FDA‑approved obesity medications, and metabolic and bariatric surgery. Members should see those obesity services treated like any other covered condition when it comes to deductibles, copays, coinsurance, and annual limits, and insurers cannot impose medication coverage rules more restrictive than the FDA indications; insurers may still use utilization management but only in the same way they use it for other conditions. This likely increases insurers’ and managed care organizations’ service and payment responsibilities and could raise their short‑term costs, while reducing barriers for patients to access medications, surgery, and recognized lifestyle programs. The bill also requires the unnamed “authority” that oversees certain public plans to apply to CMS by November 1, 2025 for federal matching funds and, if approved, to extend the same coverage requirements to those public plans and managed care organizations. The text leaves unclear which agency is the “authority” and the specific telemedicine definitions it references, and the chunk provided does not include any provisions mentioned in the act’s title about diabetes prevention, so some implementation details and scope remain uncertain.